RGNX
Companies
NASDAQ
Regenxbio Inc.
Health Care
$8.57
+$0.84 (+10.87%)
Price Chart
Overview
About RGNX
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Market Cap
$693.5M
Volume
7.4M
Avg. Volume
8.6M
P/E Ratio
-4.9166665
Dividend Yield
0.00%
Employees
376.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.76
High Correlation
Volatility
High (0.68)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Low Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, RGNX shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$693.5M
Volume7.4M
P/E Ratio-4.92
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 14, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025